{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:55:59Z","timestamp":1777881359267,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"The FIREFLEYE next study was sponsored by Bayer AG and co-funded by Regeneron Pharmaceuticals, Inc."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmol Eye Dis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1177\/25158414251321730","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T02:44:45Z","timestamp":1750819485000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Plain-language commentary: 2-year findings from the FIREFLEYE next study looking at how well aflibercept injected into affected eyes in babies with retinopathy of prematurity works and how safe it is compared with laser treatment"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8013-7597","authenticated-orcid":false,"given":"Andreas","family":"Stahl","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University Medicine Greifswald, Ferdinand Sauerbruch Stra\u00dfe, Greifswald 17475, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehiko","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Division of Neonatal Intensive Care Medicine, Department of Advanced Medicine, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Lepore","sequence":"additional","affiliation":[{"name":"Department of Geriatrics and Neuroscience, Catholic University of the Sacred Heart, A. Gemelli Foundation Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Chi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan City, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Azuma","sequence":"additional","affiliation":[{"name":"Department of Developmental and Regenerative Biology, Medical Research Institute, Institute of Science Tokyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Jacas","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Hospital Universitari Vall d\u2019Hebron, Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Athanikar","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Vitti","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Chu","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Iveli","sequence":"additional","affiliation":[{"name":"Bayer AG, Wuppertal, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Bayer, Inc., Mississauga, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Schlief","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Leal","sequence":"additional","affiliation":[{"name":"Bayer Consumer Care AG, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Schmelter","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Miller","sequence":"additional","affiliation":[{"name":"Bayer Healthcare LLC, Whippany, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evra","family":"K\u00f6f\u00fcnc\u00fc","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alistair","family":"Fielder","sequence":"additional","affiliation":[{"name":"Department of Optometry and Visual Science, City St George\u2019s, University of London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the FIREFLEYE Next Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.2147\/PHMT.S391591"},{"key":"e_1_3_4_3_2","unstructured":"Retinopathy of prematurity https:\/\/www.nei.nih.gov\/learn-about-eye-health\/eye-conditions-and-diseases\/retinopathy-prematurity (2023 accessed 10 July 2024)."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-3061"},{"key":"e_1_3_4_5_2","unstructured":"March de Ribot F Miller AM Stevenson E et al. Retinopathy of prematurity https:\/\/eyewiki.aao.org\/Retinopathy_of_Prematurity#:~:text=There%20are%20a%20number%20of strabismus%2C%20amblyopia%2C%20and%20anisometropia (2024 accessed 10 July 2024)."},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.12.1684"},{"key":"e_1_3_4_7_2","first-page":"233","article-title":"Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial","volume":"102","author":"Good WV and Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2004","unstructured":"Good WV and Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 2004; 102: 233\u2013248.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"e_1_3_4_8_2","volume-title":"Walking the ROP treatment tightrope","author":"Stuart A","year":"2015","unstructured":"Stuart A. Walking the ROP treatment tightrope. EyeNet (American Academy of Ophthalmology), https:\/\/www.aao.org\/eyenet\/article\/walking-rop-treatment-tightrope (2015)."},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31344-3"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.10564"},{"key":"e_1_3_4_12_2","unstructured":"Public summary of the evaluation of the proposed paediatric investigation plan Ranibizumab for treatment of retinopathy of prematurity https:\/\/www.ema.europa.eu\/en\/documents\/other\/public-summary-evaluation-proposed-paediatric-investigation-plan-ranibizumab-treatment-retinopathy-prematurity_en.pdf (2014 accessed 5 August 2024)."},{"key":"e_1_3_4_13_2","unstructured":"Novartis receives positive CHMP opinion for Lucentis\u00ae treatment in preterm infants with retinopathy of prematurity (ROP) a disease causing visual impairment and blindness https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-positive-chmp-opinion-lucentis-treatment-preterm-infants-retinopathy-prematurity-rop-disease-causing-visual-impairment-and-blindness#:~:text=Basel%2C%20July%2026%2C%202019%20%2D retinopathy%20of%20prematurity%20(ROP) (2019 accessed 5 August 2024)."},{"key":"e_1_3_4_14_2","unstructured":"Bayer receives positive CHMP opinion for Eylea\u2122 in the EU for treatment of preterm infants with retinopathy of prematurity https:\/\/www.bayer.com\/media\/en-us\/bayer-receives-positive-chmp-opinion-for-eylea-in-the-eu-for-treatment-of-preterm-infants-with-retinopathy-of-prematurity\/ (2022 accessed 2 July 2024)."},{"key":"e_1_3_4_15_2","unstructured":"EYLEA \u00ae approved in Japan for treatment of preterm infants with retinopathy of prematurity https:\/\/www.bayer.com\/media\/en-us\/eylea-approved-in-japan-for-treatment-of-preterm-infants-with-retinopathy-of-prematurity\/ (2022 accessed 2 July 2024)."},{"key":"e_1_3_4_16_2","unstructured":"EYLEA \u00ae (aflibercept) injection approved as the first pharmacologic treatment for preterm infants with retinopathy of prematurity (ROP) by the FDA https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/eylear-aflibercept-injection-approved-first-pharmacologic (2023 accessed 2 July 2024)."},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.8383"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.4103\/0974-620X.142592"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000783"}],"container-title":["Therapeutic Advances in Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25158414251321730","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/25158414251321730","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25158414251321730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:40:42Z","timestamp":1777596042000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/25158414251321730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":18,"alternative-id":["10.1177\/25158414251321730"],"URL":"https:\/\/doi.org\/10.1177\/25158414251321730","relation":{},"ISSN":["2515-8414","2515-8414"],"issn-type":[{"value":"2515-8414","type":"print"},{"value":"2515-8414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"article-number":"25158414251321730"}}